Refocusing Tarveda On Tumor-Targeted Mini-Drug Conjugates
Executive Summary
Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.
You may also be interested in...
Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90
Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.
Venture Funding Deals
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Golden Meditech and MD Anderson establish startup focused on umbilical cord blood-derived T-regulatory therapies. Bayer and Evotec sign their second collaboration in four years, this time focused on renal disease.